Biogen, Incorporated

Pharmaessentia Corporation

Biogen Idec Ma Inc.

Biogen Idec, Inc.

Monsanto Company

G.d. Searle & Company

Ko-Chung Lin

John Jeffrey Talley

John Nicholas Freskos

Alfredo C Castro

Michael John Clare

Steven P Adams

Craig N Zimmerman

Wen-Cherng Lee

Charles E Hammond

Julio Hernan Cuervo

Yu-Sheng Liao

Mary Beth Carter

Ronald G Almquist

Juswinder Singh

Chi B Vu

Oleh Zagrijtschuk

Christoph Klade

Rudolf Stefan Widmann

Wensen Li

Chungsun Chien

Donald Joseph Rogier

Gary Anthony Decrescenzo

Richard August Mueller

Daniel Paul Getman

Kathryn Lea Reed

John Nicholas Fresko

Robert Martin Heintz

Eric Tak Sun

Michael Lawrence Vazquez

Deborah Elizabeth Bertenshaw

Described is a method for treating an infectious disease, cancer, or myeloproliferative disease in a subject, wherein a 50 to 540 μg dose of a pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

Dosage regimen for pegylated interferon

A pegylated type I interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 &#x3bc;g dose of the pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

This invention relates to a process of synthesizing a &#x3b2;-nucleoside compound of formula (I): wherein Ris alkyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl. The process includes reacting a compound of formula (II): with a compound of formula (III): wherein Ris as defined above and X is chloride, bromide, iodide, methanesulfonate, triflate, p-toluenesulfonate, trifluoroacetate, 4-nitrophenoxy, or N-succinimidyloxy, in a solvent and in the presence of a base.

Synthesis of 5-deoxy-5'-fluorocytidine compounds

This invention relates to use protein-polymer conjugates described in the specification to treat various diseases, including disease is idiopaic myelofibrsis, polycythaemia vera, and essential thromobocythaemia.

Therapeutic use of interferon-polymer conjugates

This invention relates to a conjugate of a polymer moiety and an interferon-&#x3b2; moiety, an erythropoietin moiety, or a growth hormone moiety.

Protein-polymer conjugates

Protein-polymer conjugates are described. Also described are a method for preparing a protein-polymer conjugate and its use in treating hepatitis B virus or hepatitis C virus infection.

This invention relates to a process for stereoselectively preparing a nucleoside of the following formula: wherein R, R, and B are defined herein. The process includes reacting a furanose compound with a nucleobase in the presence of a halide salt. Also disclosed is another process for stereoselectively synthesizing an intermediate that can be used to make the starting compound in the first-mentioned process.

Stereoselective synthesis of &#x3b2;-nucleosides

Compounds of Formula I and II are disclosed as antagonists of subtype A1 adenosine receptors. These compounds are useful for treatment of various diseases and disorders, including systemic hypertension, renal failure, diabetes, asthma, an edematous condition, congestive heart failure, and renal dysfunction.

A1 adenosine receptro antagonists

The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.

Cell adhesion inhibitors

A1 adenosine receptor antagonists

Growing community of inventors

Lexington, MA, United States of America

Ko-Chung Lin